These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32176613)

  • 1. An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta.
    Zoratti MJ; Xie F; Thorlund K; Allen N; Levine M
    Healthc Policy; 2020 Feb; 15(3):90-101. PubMed ID: 32176613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
    Allen N; Walker SR; Liberti L; Sehgal C; Salek MS
    CMAJ Open; 2016; 4(4):E674-E678. PubMed ID: 28018881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of product listing agreements by Canadian provincial drug benefit plans.
    Morgan SG; Friesen MK; Thomson PA; Daw JR
    Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
    McCormick JI; Berescu LD; Tadros N
    Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-provincial use of cardiac services: the importance of data-sharing for clinical registries and outcomes research.
    Humphries KH; Carere RG; Izadnegahdar M; Galbraith PD; Knudtson ML; Ghali WA
    Can J Cardiol; 2005 Mar; 21(3):267-72. PubMed ID: 15776116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
    Lexchin J; Mintzes B
    Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.
    Gamble JM; Eurich DT; Johnson JA
    Healthc Policy; 2010 Nov; 6(2):e117-44. PubMed ID: 22043227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?
    Rawson N
    J Popul Ther Clin Pharmacol; 2017 Dec; 24(3):90-98. PubMed ID: 29432671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common Drug Review recommendations: an evidence base for expectations?
    Rocchi A; Miller E; Hopkins RB; Goeree R
    Pharmacoeconomics; 2012 Mar; 30(3):229-46. PubMed ID: 22283689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.
    Paradis PE; Mishagina N; Carter V; Raymond V
    Healthc Q; 2012; 15(2):52-60. PubMed ID: 22688206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.
    Ismail Z; Peacock SJ; Kovacic L; Hoch JS
    Int J Technol Assess Health Care; 2017 Jan; 33(4):481-486. PubMed ID: 28871898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of policies to reduce blood glucose test strip utilization and costs in Canada.
    Gomes T; Martins D; Cheng L; Kratzer J; Juurlink DN; Shah BR; Mamdani MM; Paterson JM; Law MR
    Can J Public Health; 2015 Apr; 106(4):e210-6. PubMed ID: 26285192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.
    Scobie AC; Mackinnon NJ
    Healthc Policy; 2010 Feb; 5(3):100-14. PubMed ID: 21286272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
    Bae G; Bae EY; Bae S
    Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating economic evaluations into decision-making: the Ontario experience.
    Laupacis A
    Med Care; 2005 Jul; 43(7 Suppl):15-9. PubMed ID: 16056004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
    Larouche G; Chiquette J; Plante M; Pelletier S; Simard J; Dorval M
    Can Assoc Radiol J; 2016 Nov; 67(4):308-312. PubMed ID: 27318890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.